Distribution of the homologous recombination-related (HRR) genesmutationsand HRD in breast cancer
Conditions
Interventions
case series:NA
Sponsors
Sun Yat Sen Memorial Hospital of Sun Yat sen University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female patients who have pathologically documented breast cancer that has a history of HER2-low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) with a validated assay ASCO/CAP guidelines in the metastatic setting; 2. Femalepatients must be at least aged 18 years; 3. ECOG Performance Status of 0 or 1; 4. Patients with operable primary breast cancer who underwent radical surgery and no patients received preoperative neoadjuvant therapy; 5. No distant metastasis occurred; 6. Patient must have adequate tumor andbloodsample for biomarker assessment.
Exclusion criteria
Exclusion criteria: 1. Recurrent or advanced metastatic breast cancer; 2. Bilateral breast cancer (including multifocal breast cancer, all histological lesions were HER2 1+ or 2+, not detected by FISH amplification and HR positive according to ASCO guidelines); 3. Other malignant tumors within 5 years; 4. Clinical diagnosis and treatment information is incomplete.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Homologous recombination repair, HRR;Homologous recombination deficiency, HRD; | — |
Countries
China
Contacts
Public ContactGong Chang
Sun Yat Sen Memorial Hospital of Sun Yat sen University
Outcome results
None listed